Idiopathic Pulmonary Fibrosis Treatment Market_PR

1. Idiopathic Pulmonary Fibrosis Treatment Market Outlook and Forecasts By Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysis Idiopathic Pulmonary Fibrosis Treatment Market Size by Research Nester Reveals the Market to Grow with a CAGR of 7.1% During 2025-2037 and Attain USD 7.9 Billion by 2037 Research Nester assesses the growth and market size of global idiopathic pulmonary fibrosis treatment market which is anticipated to be on account of the rising awareness about IPF and ILD, among healthcare practitioners and patients as well. Research Nester’s recent market research analysis on “Idiopathic Pulmonary Fibrosis Treatment Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor’s analysis and a detailed overview of the global idiopathic pulmonary fibrosis treatment market in terms of market segmentation by treatment type, route of administration, age group, end use, and by region. Increasing Incidence and Prevalence of Idiopathic Pulmonary Fibrosis to Promote Global Market Share of Idiopathic Pulmonary Fibrosis Treatment According to the NLM, idiopathic pulmonary fibrosis treatment accounts for 17–37% of all cases of interstitial lung disease (ILD) and accounts for the maximum recurrent and severe idiopathic interstitial pneumonias (IIPs). It is an expensive disease with treatment costs of around USD 25,000 per person, every year. The growing patient population directly correlates with an increased demand for effective treatments, thereby driving market growth. Additionally, greater recognition of IPF among healthcare providers leads to earlier intervention and management. It gives rise to improved diagnostic capabilities, and more cases being identified, particularly among the aging population, further propelling the idiopathic pulmonary fibrosis treatment market expansion with new product launches. For instance, in February 2022, Boehringer Ingelheim received U.S. FDA Breakthrough Therapy DesignationBI 1015550, a novel investigational therapy, for the treatment of IPF. Some of the major growth factors and challenges that are associated with the growth of the global idiopathic pulmonary fibrosis treatment market are: Growth Drivers: Rising focus on Quality-of-Life (QoL) Studies Development of Antifibrotic Combinations Challenges:

2. While antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow disease progression, their effects are often modest, leading to a need for more effective options. Additionally, these medicines can cause side effects including gastrointestinal issues, fatigue, and liver function abnormalities, which may deter patient adherence and impact the overall quality of life. This as a result hampers optimal patient management and underscores the urgent need for novel therapies offering improved efficacy with better tolerability. Access our detailed report at: https://www.researchnester.com/reports/idiopathic-pulmonary-fibrosis- treatment-market/6636 By age group, the global idiopathic pulmonary fibrosis treatment market is segmented into adult and geriatric. The adult segment is anticipated to garner the highest revenue by the end of 2037 by growing at a significant CAGR over the forecast period. IPF primarily affects individuals aged 50 and above. This demographic is at a higher risk owing to age-related decline in lung function and a higher likelihood of comorbidities that can exacerbate respiratory issues. Lifestyle factors such as smoking history, occupational exposures, and environmental pollutants prevalent among this section of the population further increase their risks of developing IPF. By region, the Europe idiopathic pulmonary fibrosis treatment market is to generate considerable revenue by the end of 2037. The major drivers include advanced medical infrastructure and supportive regulatory frameworks. The region’s market also benefits from increasing awareness and early diagnosis of the disease. Furthermore, the adoption of telemedicine enabling remote patient monitoring which is vital for managing progressive diseases such as IPF is also thriving. This is further projected to boost the region’s market growth significantly. Customized report@ https://www.researchnester.com/customized-reports- 6636 This report also provides the existing competitive scenario of some of the key players of the market, including Bumrungrad International Hospital, Cedars-Sinai, Cleveland Clinic, Bristol-Myers Squibb Company, Cipla Inc., FibroGen, Inc., Galapagos NV, and others. Request Report Sample@ https://www.researchnester.com/sample-request- 6636 Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries,

3. conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties. Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919